vs
Amphastar Pharmaceuticals, Inc.（AMPH）与KADANT INC（KAI）财务数据对比。点击上方公司名可切换其他公司
KADANT INC的季度营收约是Amphastar Pharmaceuticals, Inc.的1.5倍（$271.6M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 10.2%，领先3.1%），KADANT INC同比增速更快（-0.0% vs -1.8%），KADANT INC自由现金流更多（$44.1M vs $24.6M），过去两年KADANT INC的营收复合增速更高（6.7% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Kadant Inc.创立于1991年，最初是Thermo Electron的子公司，部分股权私有、部分公开交易，2001年完成完全分拆并启用现名。公司服务于造纸、废纸回收、木材加工、物料搬运等多个加工领域，是业务覆盖亚洲、欧洲、北美、南美的跨国企业。
AMPH vs KAI — 直观对比
营收规模更大
KAI
是对方的1.5倍
$183.1M
营收增速更快
KAI
高出1.8%
-1.8%
净利率更高
AMPH
高出3.1%
10.2%
自由现金流更多
KAI
多$19.5M
$24.6M
两年增速更快
KAI
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $271.6M |
| 净利润 | $24.4M | $27.7M |
| 毛利率 | 46.8% | 45.2% |
| 营业利润率 | 19.4% | 15.7% |
| 净利率 | 13.3% | 10.2% |
| 营收同比 | -1.8% | -0.0% |
| 净利润同比 | -35.7% | -12.2% |
| 每股收益（稀释后） | $0.51 | $2.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHKAI
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $271.6M | ||
| Q2 25 | $174.4M | $255.3M | ||
| Q1 25 | $170.5M | $239.2M | ||
| Q4 24 | $186.5M | $258.0M | ||
| Q3 24 | $191.2M | $271.6M | ||
| Q2 24 | $182.4M | $274.8M | ||
| Q1 24 | $171.8M | $249.0M |
净利润AMPHKAI
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $27.7M | ||
| Q2 25 | $31.0M | $26.2M | ||
| Q1 25 | $25.3M | $24.1M | ||
| Q4 24 | $38.0M | $24.0M | ||
| Q3 24 | $40.4M | $31.6M | ||
| Q2 24 | $37.9M | $31.3M | ||
| Q1 24 | $43.2M | $24.7M |
毛利率AMPHKAI
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 45.2% | ||
| Q2 25 | 49.6% | 45.9% | ||
| Q1 25 | 50.0% | 46.1% | ||
| Q4 24 | 46.5% | 43.4% | ||
| Q3 24 | 53.3% | 44.7% | ||
| Q2 24 | 52.2% | 44.4% | ||
| Q1 24 | 52.4% | 44.6% |
营业利润率AMPHKAI
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | 15.7% | ||
| Q2 25 | 24.2% | 15.4% | ||
| Q1 25 | 21.9% | 14.9% | ||
| Q4 24 | 24.2% | 14.3% | ||
| Q3 24 | 29.8% | 18.0% | ||
| Q2 24 | 30.3% | 17.6% | ||
| Q1 24 | 27.9% | 14.8% |
净利率AMPHKAI
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 10.2% | ||
| Q2 25 | 17.8% | 10.2% | ||
| Q1 25 | 14.8% | 10.1% | ||
| Q4 24 | 20.4% | 9.3% | ||
| Q3 24 | 21.1% | 11.6% | ||
| Q2 24 | 20.8% | 11.4% | ||
| Q1 24 | 25.1% | 9.9% |
每股收益（稀释后）AMPHKAI
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $2.35 | ||
| Q2 25 | $0.64 | $2.22 | ||
| Q1 25 | $0.51 | $2.04 | ||
| Q4 24 | $0.74 | $2.04 | ||
| Q3 24 | $0.78 | $2.68 | ||
| Q2 24 | $0.73 | $2.66 | ||
| Q1 24 | $0.81 | $2.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $124.5M |
| 总债务越低越好 | $608.7M | $254.6M |
| 股东权益账面价值 | $788.8M | $949.8M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资AMPHKAI
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $124.5M | ||
| Q2 25 | $231.8M | $95.3M | ||
| Q1 25 | $236.9M | $91.7M | ||
| Q4 24 | $221.6M | $94.7M | ||
| Q3 24 | $250.5M | $88.4M | ||
| Q2 24 | $217.8M | $73.8M | ||
| Q1 24 | $289.6M | $81.4M |
总债务AMPHKAI
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | $254.6M | ||
| Q2 25 | $607.7M | $245.7M | ||
| Q1 25 | $603.9M | $273.5M | ||
| Q4 24 | $601.6M | $285.2M | ||
| Q3 24 | $596.4M | $323.2M | ||
| Q2 24 | $586.9M | $342.0M | ||
| Q1 24 | $594.0M | $306.8M |
股东权益AMPHKAI
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $949.8M | ||
| Q2 25 | $757.5M | $926.0M | ||
| Q1 25 | $751.3M | $876.0M | ||
| Q4 24 | $732.3M | $847.1M | ||
| Q3 24 | $727.7M | $851.7M | ||
| Q2 24 | $713.3M | $807.7M | ||
| Q1 24 | $672.4M | $782.7M |
总资产AMPHKAI
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.4B |
负债/权益比AMPHKAI
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | 0.27× | ||
| Q2 25 | 0.80× | 0.27× | ||
| Q1 25 | 0.80× | 0.31× | ||
| Q4 24 | 0.82× | 0.34× | ||
| Q3 24 | 0.82× | 0.38× | ||
| Q2 24 | 0.82× | 0.42× | ||
| Q1 24 | 0.88× | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $47.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $44.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 16.2% |
| 资本支出强度资本支出/营收 | 4.5% | 1.2% |
| 现金转化率经营现金流/净利润 | 1.35× | 1.70× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $145.9M |
8季度趋势，按日历期对齐
经营现金流AMPHKAI
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $47.3M | ||
| Q2 25 | $35.6M | $40.5M | ||
| Q1 25 | $35.1M | $22.8M | ||
| Q4 24 | $29.0M | $51.9M | ||
| Q3 24 | $60.0M | $52.5M | ||
| Q2 24 | $69.1M | $28.1M | ||
| Q1 24 | $55.3M | $22.8M |
自由现金流AMPHKAI
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $44.1M | ||
| Q2 25 | $25.0M | $36.5M | ||
| Q1 25 | $24.4M | $19.0M | ||
| Q4 24 | $16.6M | $46.3M | ||
| Q3 24 | $46.2M | $48.3M | ||
| Q2 24 | $63.1M | $23.1M | ||
| Q1 24 | $46.5M | $16.6M |
自由现金流率AMPHKAI
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 16.2% | ||
| Q2 25 | 14.3% | 14.3% | ||
| Q1 25 | 14.3% | 7.9% | ||
| Q4 24 | 8.9% | 17.9% | ||
| Q3 24 | 24.1% | 17.8% | ||
| Q2 24 | 34.6% | 8.4% | ||
| Q1 24 | 27.1% | 6.7% |
资本支出强度AMPHKAI
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 1.2% | ||
| Q2 25 | 6.1% | 1.6% | ||
| Q1 25 | 6.3% | 1.6% | ||
| Q4 24 | 6.7% | 2.2% | ||
| Q3 24 | 7.2% | 1.5% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 5.1% | 2.5% |
现金转化率AMPHKAI
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.70× | ||
| Q2 25 | 1.15× | 1.55× | ||
| Q1 25 | 1.39× | 0.95× | ||
| Q4 24 | 0.76× | 2.16× | ||
| Q3 24 | 1.48× | 1.66× | ||
| Q2 24 | 1.82× | 0.90× | ||
| Q1 24 | 1.28× | 0.92× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
KAI
| Flow Control | $94.8M | 35% |
| Capital | $83.2M | 31% |
| Material Handling Systems | $70.3M | 26% |
| Transferred Over Time | $17.1M | 6% |
| Other | $6.1M | 2% |
